Display options
Cite
Wei T, Jia Y, Xue W, et al. Nutritional Effects of the Enteral Nutritional Formula on Regulation of Gut Microbiota and Metabolic Level in Type 2 Diabetes Mellitus Mice. Diabetes Metab Syndr Obes. 2021;14:1855-1869doi: 10.2147/DMSO.S301454.
Wei, T., Jia, Y., Xue, W., Ma, M., & Wu, W. (2021). Nutritional Effects of the Enteral Nutritional Formula on Regulation of Gut Microbiota and Metabolic Level in Type 2 Diabetes Mellitus Mice. Diabetes, metabolic syndrome and obesity : targets and therapy, 141855-1869. https://doi.org/10.2147/DMSO.S301454
Wei, Ting, et al. "Nutritional Effects of the Enteral Nutritional Formula on Regulation of Gut Microbiota and Metabolic Level in Type 2 Diabetes Mellitus Mice." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 14 (2021): 1855-1869. doi: https://doi.org/10.2147/DMSO.S301454
Wei T, Jia Y, Xue W, Ma M, Wu W. Nutritional Effects of the Enteral Nutritional Formula on Regulation of Gut Microbiota and Metabolic Level in Type 2 Diabetes Mellitus Mice. Diabetes Metab Syndr Obes. 2021 Apr 28;14:1855-1869. doi: 10.2147/DMSO.S301454. eCollection 2021. PMID: 33953585; PMCID: PMC8089093.
Copy Download .nbib Format: NLM
Share it on

Diabetes Metab Syndr Obes. 2021 Apr 28;14:1855-1869. doi: 10.2147/DMSO.S301454. eCollection 2021.

Nutritional Effects of the Enteral Nutritional Formula on Regulation of Gut Microbiota and Metabolic Level in Type 2 Diabetes Mellitus Mice.

Diabetes, metabolic syndrome and obesity : targets and therapy

Ting Wei, Ye Jia, Wei Xue, Ming Ma, Wenhui Wu

Affiliations

  1. College of Food Science and Engineering, Shanghai Ocean University, Shanghai, 201306, People's Republic of China.

PMID: 33953585 PMCID: PMC8089093 DOI: 10.2147/DMSO.S301454

Abstract

PURPOSE: Due to the adverse effects of antidiabetic drugs, nowadays, nutraceuticals have been of much interest to investigators. Therefore, the present study aimed to explore the potential effects of enteral nutritional (EN) formulas on the gut microbiota and metabolic regulation of type 2 diabetes mellitus (T2DM) mice and compare the differences between whey protein and soy protein.

METHODS: EN formulas made of whey protein or soy protein were administered for five weeks and then mice tissue samples were obtained to examine the metabolic parameters and histopathology of the pancreas, liver, jejunum and colon. 16S rRNA V3-V4 region gene sequencing was used to analyze the changes in the gut microbiota.

RESULTS: After the five-week intervention, the alpha diversity had recovered slightly, and the soy protein group (SPG) achieved a better effect than the whey protein group (LPG). The overall composition of gut microbiota was regulated. The abundance of Bacteroidetes and TM7 had raised significantly and the abundance of Firmicutes and Deferribacteres had declined after treatment, with no significant difference between the LPG and SPG. The types of beneficial bacteria were increased at the genus and species level. The level of hexokinase (HK) and pyruvate kinase (PK) had significantly recovered and inhibited the level of α-glucosidase. In addition, the EN formulas treatment reduced the levels of inflammatory factor (TNF-α) in liver and muscle. The level of glucose transporter type 2 (GLUT-2) levels in the liver and intestine also significantly increased. Moreover, the metabolism regulation of the SPG was better than that of the LPG. The EN formulas treatment improved the pancreas, liver, jejunum and colon histology.

CONCLUSION: The EN formulas regulated the overall structure of the gut microbiota and improved the metabolic level in streptozotocin/high-fat diet (STZ/HFD) diabetic mice. Therefore, EN formula may potentially become an effective nutritional adjunctive therapy for T2DM.

© 2021 Wei et al.

Keywords: 16S rRNA gene sequencing; enteral nutritional formula; gut microbiota; soy protein; type 2 diabetes mellitus; whey protein

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

  1. Biosci Biotechnol Biochem. 1997 Jan;61(1):177-8 - PubMed
  2. Biomed Pharmacother. 2019 Sep;117:109138 - PubMed
  3. Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):397-411 - PubMed
  4. Nature. 2015 Dec 10;528(7581):262-266 - PubMed
  5. Microb Pathog. 2019 Feb;127:48-55 - PubMed
  6. Nestle Nutr Workshop Ser Pediatr Program. 2008;62:127-37; discussion 137-40 - PubMed
  7. Nature. 2012 Oct 4;490(7418):55-60 - PubMed
  8. Nature. 2012 Sep 13;489(7415):242-9 - PubMed
  9. J Agric Food Chem. 2018 Jun 13;66(23):5821-5831 - PubMed
  10. Diabetologia. 2007 Nov;50(11):2374-83 - PubMed
  11. Microbiome. 2018 Nov 8;6(1):200 - PubMed
  12. Int Immunopharmacol. 2020 Mar 6;82:106368 - PubMed
  13. Int J Biol Macromol. 2018 Aug;115:711-717 - PubMed
  14. Food Funct. 2020 May 1;11(5):4249-4258 - PubMed
  15. Gut. 2018 Aug;67(8):1445-1453 - PubMed
  16. Cell Metab. 2010 May 5;11(5):345-6 - PubMed
  17. Diabetologia. 2015 Feb;58(2):221-32 - PubMed
  18. J Pharmacol Exp Ther. 2014 Sep;350(3):657-64 - PubMed
  19. Microb Pathog. 2019 Dec;137:103774 - PubMed
  20. Nutrition. 2020 May;73:110700 - PubMed
  21. BMC Complement Altern Med. 2012 Sep 11;12:151 - PubMed
  22. Curr Opin Pharmacol. 2019 Dec;49:1-5 - PubMed
  23. Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15718-23 - PubMed
  24. PLoS One. 2012;7(6):e39748 - PubMed
  25. J Nutr Sci. 2015 Oct 12;4:e33 - PubMed
  26. Mol Metab. 2016 Nov 04;6(1):61-72 - PubMed
  27. Cell Res. 2019 Jul;29(7):516-532 - PubMed
  28. Cell Biosci. 2017 Oct 25;7:54 - PubMed
  29. Crit Rev Food Sci Nutr. 2020;60(4):670-683 - PubMed
  30. ISME J. 2015 Jan;9(1):1-15 - PubMed
  31. Nature. 2006 Dec 21;444(7122):1022-3 - PubMed
  32. Appetite. 2019 Oct 1;141:104322 - PubMed
  33. Curr Opin Clin Nutr Metab Care. 2007 Nov;10(6):729-34 - PubMed
  34. Diabetes. 2000 Oct;49(10):1643-8 - PubMed
  35. J Diabetes Investig. 2012 Aug 20;3(4):352-3 - PubMed
  36. Pharmacol Res. 2019 Oct;148:104344 - PubMed
  37. iScience. 2020 Sep 2;23(9):101522 - PubMed
  38. J Diabetes Res. 2016;2016:2641248 - PubMed
  39. Diabetes. 2011 Nov;60(11):2775-86 - PubMed
  40. Diabetes Care. 2005 Sep;28(9):2267-79 - PubMed
  41. Fitoterapia. 2019 Apr;134:270-289 - PubMed
  42. Public Health Nutr. 2001 Apr;4(2B):499-515 - PubMed
  43. Diabetologia. 2010 Apr;53(4):606-13 - PubMed
  44. Metabolism. 2017 May;70:107-115 - PubMed
  45. Pharmacol Res. 2019 Oct;148:104403 - PubMed
  46. Int Immunopharmacol. 2015 Sep;28(1):744-50 - PubMed
  47. mBio. 2015 Feb 24;6(2):e02554 - PubMed
  48. Diabetes. 2007 Jul;56(7):1761-72 - PubMed
  49. Food Chem Toxicol. 2011 Dec;49(12):3104-11 - PubMed
  50. PLoS One. 2009 Sep 09;4(9):e6958 - PubMed
  51. Am J Clin Nutr. 2004 Nov;80(5):1246-53 - PubMed
  52. Food Funct. 2014 Nov;5(11):2850-60 - PubMed
  53. Int J Biol Macromol. 2018 Apr 15;110:276-284 - PubMed
  54. Nutrients. 2019 Aug 07;11(8): - PubMed
  55. J Nutr Biochem. 2019 Aug;70:1-27 - PubMed
  56. Diabetes Res Clin Pract. 2018 Mar;137:190-199 - PubMed
  57. BMC Complement Altern Med. 2015 Feb 07;15:19 - PubMed
  58. J Nutr Biochem. 2007 May;18(5):313-21 - PubMed
  59. J Clin Invest. 2005 May;115(5):1111-9 - PubMed
  60. Mol Cell Endocrinol. 2005 Jun 15;237(1-2):49-57 - PubMed
  61. Biomed Pharmacother. 2016 Dec;84:1585-1594 - PubMed
  62. ISME J. 2019 Jun;13(6):1379-1390 - PubMed
  63. Environ Microbiol. 2010 Feb;12(2):304-14 - PubMed
  64. Nutrients. 2014 Nov 18;6(11):5142-52 - PubMed
  65. J Pharm Biomed Anal. 2020 Nov 30;191:113617 - PubMed
  66. PLoS One. 2010 Feb 05;5(2):e9085 - PubMed
  67. Proc Natl Acad Sci U S A. 2013 May 28;110(22):9066-71 - PubMed
  68. Carbohydr Polym. 2013 Oct 15;98(1):8-16 - PubMed
  69. Curr Opin Clin Nutr Metab Care. 2010 Jul;13(4):432-8 - PubMed
  70. J Med Chem. 2018 Apr 26;61(8):3609-3625 - PubMed
  71. Benef Microbes. 2015;6(4):431-9 - PubMed
  72. Trends Endocrinol Metab. 2003 Apr;14(3):137-45 - PubMed
  73. Nat Rev Endocrinol. 2019 May;15(5):261-273 - PubMed

Publication Types